You are here: Industry Insights > Market News > Zydus’ Nesher Pharma gets US FDA nods for influenza drug

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Zydus’ Nesher Pharma gets US FDA nods for influenza drug

expressbpdSeptember 19, 2017

Tag: Zydus’ Nesher Pharma , US FDA , influenza drug

Favorites

The drug will be produced at Nesher Pharmaceuticals manufacturing facility located at St Louis, US

Zydus Cadila’s Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market Oseltamivir powder for oral suspension 6 mg/ml which is used in treatment and prevention of influenza.

The drug will be produced at Nesher Pharmaceuticals manufacturing facility located at St Louis, US, Zydus Cadila said.

The group now has more than 150 approvals and has so far filed over 300 Abbreviated New Drug Applications (ANDAs) since the commencement of the company’s filing process.

Previous:Fosun Pharma to acquire 74 per cent stake in Gland Pharma

Next:Lupin appoints Jim Loerop as Chief Corporate Development Officer

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Zydus’ Nesher Pharma gets US FDA nods for influenza drug | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Zydus’ Nesher Pharma gets US FDA nods for influenza drug

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Zydus’ Nesher Pharma gets US FDA nods for influenza drug

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>